Long-Term Outcomes and Prognostic Factors in Metastatic ALK-Rearranged Non-Small Cell Lung Cancer Treated with ALK Tyrosine Kinase Inhibitors: Real-World Evidence from a High-Volume Thoracic Diseases Center. (PubMed, Cancers (Basel)) - Sep 16, 2026 - "Median progression-free survival (PFS) durations were 47.5, 23.0, and 14.9 months for alectinib, brigatinib, and crizotinib, respectively. ECOG performance status, histological subtype, and PD-L1 expression were independent prognostic factors for OS. First-line lorlatinib findings suggest durable disease control but remain preliminary and require confirmation with longer follow-up."
Biomarker • HEOR • IO biomarker • Journal • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • PD-L1
|
|
Esra Zeynelgil; Nesrin Gürçay; Oktay Ünsal; Serdar Karakaya; Yakup Düzköprü
|